Joshua Hare - 13 Jun 2025 Form 4 Insider Report for Longeveron Inc. (LGVN)

Role: Chief Scientific Officer, Director, 10%+ Owner
Signature: /s/ Paul T. Lehr, attorney-in-fact
Issuer symbol: LGVN
Transactions as of: 13 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 17 Jun 2025, 18:00:04 UTC
Previous filing: 16 May 2025
Next filing: 03 Jul 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Hare Joshua	Chief Scientific Officer, Director, 10%+ Owner	1951 NW 7TH AVENUE, SUITE 520, MIAMI	/s/ Paul T. Lehr, attorney-in-fact	17 Jun 2025	0001449392

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGVN	Stock Option (right to buy)	Award	$0	+184,878		$0.000000	184,878	13 Jun 2025	Common Stock	184,878	$1.49	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option will 100% cliff vest on July 1, 2025. The option was administratively granted on April 11, 2025 contingent on the approval by the Company's stockholders of an amendment to the Company's 2021 Incentive Award Plan (as amended and restated to date) (the "Plan") to increase the number of shares available for awards under the Plan at the 2025 Annual Meeting of Stockholders held on June 13, 2025 (the "Annual Meeting"). This stockholder approval contingency was satisfied upon approval of the share increase at the Annual Meeting.

Content

The option will 100% cliff vest on July 1, 2025. The option was administratively granted on April 11, 2025 contingent on the approval by the Company's stockholders of an amendment to the Company's 2021 Incentive Award Plan (as amended and restated to date) (the "Plan") to increase the number of shares available for awards under the Plan at the 2025 Annual Meeting of Stockholders held on June 13, 2025 (the "Annual Meeting"). This stockholder approval contingency was satisfied upon approval of the share increase at the Annual Meeting.